A Study of VS-7375 in People With Non-Small Cell Lung Cancer (NSCLC)

Full Title

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.

Protocol
26-302
Phase
Phase II (phase 2)
Investigator
Kathryn C. Arbour
Co-Investigators
Mark Awad
Piro Lito
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07659782
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description